This site is intended for Healthcare professionals only.

Medical management of microscopic colitis: American Gastroenterological Association Institute guideline


Medical management of microscopic colitis: American Gastroenterological Association Institute guideline

Microscopic colitis is characterized by chronic watery diarrhea caused by inflammation in the colon and diagnosed by colonic biopsy. With a predilection for those 60 years of age or older, it comprises 2 subtypes, lymphocytic colitis and collagenous colitis; there is a female predominance in the latter.

Microscopic colitis is not associated with increased mortality, although symptoms can lead to impaired quality of life. Unlike other inflamma- tory colitides, there is no evidence that the persistence of histological inflammation portends long-term unfavorable outcomes such as colorectal cancer or need for surgery.

In 2016, American Gastroenterological Association Institute came out with Guideline on the Medical Management of Microscopic Colitis

Following are the major recommendations of the guidelines:

  1. In patients with symptomatic microscopic colitis (MC), the American Gastroenterological Association (AGA) Institute recommends treatment with budesonide over no treatment for the induction of clinical remission. (Strong recommendation, Moderate quality of evidence)
  2. In patients with symptomatic MC, the AGA recommends treatment with budesonide over mesalamine for the induction of clinical remission. (Strong recommendation, High quality of evidence)
  3. In patients with symptomatic MC in whom budesonide therapy is not feasible, the AGA suggests treatment with mesalamine over no treatment for the induction of clinical remission. (Conditional recommendation, Moderate quality of evidence)
  4. In patients with symptomatic MC in whom budesonide therapy is not feasible, the AGA suggests treatment with bismuth salicylate over no treatment for the induction of clinical remission. (Conditional recommendation, Low quality of evidence)
  5. In patients with symptomatic MC in whom budesonide therapy is not feasible, the AGA suggests treatment with prednisolone (or prednisone) over no treatment for the induction of clinical remission. (Conditional recommendation, Very low quality of evidence)
  6. In patients with symptomatic MC, the AGA suggests against combination therapy with cholestyramine and mesalamine over mesalamine alone for the induction of clinical remission. (Conditional recommendation, Low quality of evidence)
  7. In patients with symptomatic MC, the AGA suggests against treatment with Boswellia serrata over no treatment for the induction of clinical remission. (Conditional recommendation, Low quality of evidence)
  8. In patients with symptomatic MC, the AGA suggests against treatment with probiotics over no treatment for the induction of clinical remission. (Conditional recommendation, Low quality of evidence)
  9. For patients with recurrence of symptoms following discontinuation of induction therapy for MC, the AGA recommends budesonide for maintenance of clinical remission. (Strong recommendation, Moderate quality of evidence)

For detailed guidelines, click on the following link:

http://www.gastrojournal.org/article/S0016-5085(15)01625-X/pdf

The following two tabs change content below.
supriya kashyap

supriya kashyap

Supriya Kashyap Joined Medical Dialogue as Reporter in 2015 . she covers all the medical specialty news in different medical categories. She also covers the Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in medical filed. She is a graduate from Delhi University. She can be contacted at supriya.kashyap@medicaldialogues.in Contact no. 011-43720751
Source: AGA

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted